Gallbladder cancer in Chile: What have we learned?

Current Opinion in Gastroenterology

Volumn 31, Issue 3, 2015, Pages 269-275

  Roa, Iván ^a   De Aretxabala, Xabier ^b  

^a Creative Bioscience   (Chile)

^b UNIVERSIDAD DEL DESARROLLO   (Chile)

Author keywords

carcinogenesis; gallbladder neoplasm; molecular pathology

Indexed keywords

B RAF KINASE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53; RAS PROTEIN; SMAD4 PROTEIN; ANTINEOPLASTIC AGENT;

CANCER STAGING; CHILE; CHRONIC CHOLECYSTITIS; DNA METHYLATION; DYSPLASIA; EARLY CANCER; EARLY DIAGNOSIS; GALLBLADDER; GALLBLADDER CANCER; GENE MUTATION; HISTONE ACETYLATION; HUMAN; MOLECULAR PATHOLOGY; NEXT GENERATION SEQUENCING; REVIEW; CHOLECYSTECTOMY; COST BENEFIT ANALYSIS; GALLBLADDER NEOPLASMS; GENETIC PREDISPOSITION; GENETICS; INCIDENCE; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; CHILE; CHOLECYSTECTOMY; COST-BENEFIT ANALYSIS; EARLY DIAGNOSIS; GALLBLADDER NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MOLECULAR TARGETED THERAPY;

EID: 84928562165     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0000000000000164     Document Type: Review

References (86)

1. Eslick GD. Epidemiology of gallbladder cancer. Gastroenterol Clin North Am 2010; 39:307-330.
2. Andia ME, Hsing AW, Andreotti G, Ferreccio C. Geographic variation of gallbladder cancer mortality and risk factors in Chile: A population-based ecologic study. Int J Cancer 2008; 123:1411-1416.
3. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol 2014; 6:99-109.
4. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver 2012; 6:172-187.
5. Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001; 51:349-364.
6. de Aretxabala X, Riedeman P, Burgos L, et al. Gallbladder cancer. Casecontrol study. Rev Med Chil 1995; 123:581-586.
7. Bertran E, Heise K, Andia ME, Ferreccio C. Gallbladder cancer: incidence and survival in a high-risk area of Chile. Int J Cancer 2010; 127:2446-2454.
8. Wernberg JA, Lucarelli DD. Gallbladder cancer. Surg Clin North Am 2014; 94:343-360.
9. Randi G, Malvezzi M, Levi F, et al. Epidemiology of biliary tract cancers: An update. Ann Oncol 2009; 20:146-159.
10. Dutta U. Gallbladder cancer: can newer insights improve the outcome? J Gastroenterol Hepatol 2012; 27:642-653.
11. Chianale J, Valdivia G, del Pino G, Nervi F. Gallbladder cancer mortality in Chile and its relation to cholecystectomy rates. An analysis of the last decade. Rev Med Chil 1990; 118:1284-1288.
12. Perez-Ayuso RM, Hernandez V, Gonzalez B, et al. Natural history of cholelithiasis and incidence of cholecystectomy in an urban and a Mapuche rural area. Rev Med Chil 2002; 130:723-730.
13. Roa I, Araya JC, Villaseca M, et al. Gallbladder cancer in a high risk area: morphological features and spread patterns. Hepatogastroenterology 1999; 46:1540-1546.
14. Ministry of Health. Clinical guide: Cholecystectomy adult preventive 35 to 49 years. Santiago: Health Ministry, 2010. http://web.minsal.cl/portal/url/item/722 05a1420599f92e04001011f016d02.pdf. [Accessed 5 December 2014].
15. Roa I, Ibacache G, Munoz S, de Aretxabala X. Gallbladder cancer in Chile: pathologic characteristics of survival and prognostic factors: Analysis of 1366 cases. Am J Clin Pathol 2014; 141:675-682.
16. Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol 2006; 20:981-996.
17. Roa I, Ibacache G, Roa J, et al. Gallstones and gallbladder cancer-volume and weight of gallstones are associated with gallbladder cancer: A case-control study. J Surg Oncol 2006; 93:624-628.
18. Moerman CJ, Bueno-de-Mesquita HB. The epidemiology of gallbladder cancer: lifestyle related risk factors and limited surgical possibilities for prevention. Hepatogastroenterology 1999; 46:1533-1539.
19. Srivastava K, Srivastava A, Kumar A, Mittal B. Gallbladder cancer predisposition: A multigenic approach to DNA-repair, apoptotic and inflammatory pathway genes. PLoS One 2011; 6:e16449.
20. Li Y, Zhang J, Ma H. Chronic inflammation and gallbladder cancer. Cancer Lett 2014; 345:242-248.
21. Hsing AW, Sakoda LC, Rashid A, et al. Variants in inflammation genes and the risk of biliary tract cancers and stones: A population-based study in China. Cancer Res 2008; 68:6442-6452.
22. Morine Y, Shimada M, Takamatsu H, et al. Clinical features of pancreaticobiliary maljunction: update analysis of 2nd Japan-nationwide survey. J Hepatobiliary Pancreat Sci 2013; 20:472-480.
23. Roland G, Ruiz A, ArrivéL. Gallbladder carcinoma with anomalous pancreaticobiliary junction. Clin Res Hepatol Gastroenterol 2011; 35:779-780.
24. Horaguchi J, Fujita N, Kamisawa T, et al. Pancreatobiliary reflux in individuals with a normal pancreaticobiliary junction: A prospective multicenter study [10. 1007/s00535-013-0837-7]. J Gastroenterol 2014; 49:875-881.
25. Deng YL, Cheng NS, Lin YX, et al. Relationship between pancreaticobiliary maljunction and gallbladder carcinoma: meta-analysis. Hepatobiliary Pancreat Dis Int 2011; 10:570-580.
26. Funabiki T, Matsubara T, Miyakawa S, Ishihara S. Pancreaticobiliary maljunction and carcinogenesis to biliary and pancreatic malignancy. Langenbecks Arch Surg 2009; 394:159-169.
27. Chhabra D, Oda K, Jagannath P, et al. Chronic heavy metal exposure and gallbladder cancer risk in India, a comparative study with Japan. Asian Pac J Cancer Prev 2012; 13:187-190.
28. Fernŕ ndez-Navarro P, Garća-Pérez J, Ramis R, et al. Proximity to mining industry and cancer mortality. Sci Total Environ 2012; 435-436:66-73.
29. Garća-Pérez J, López-Cima MF, Pérez-Gómez B, et al. Mortality due to tumours of the digestive system in towns lying in the vicinity of metal production and processing installations. Sci Total Environ 2010; 408:3102-3112.
30. Bŕez S, Tsuchiya Y, Calvo A, et al. Genetic variants involved in gallstone formation and capsaicin metabolism, and the risk of gallbladder cancer in Chilean women. World J Gastroenterol 2010; 16:372-378.
31. Tsuchiya Y, Terao M, Okano K, et al. Mutagenicity and mutagens of the red chili pepper as gallbladder cancer risk factor in Chilean women. Asian Pac J Cancer Prev 2011; 12:471-476.
32. Vucenik I, Stains JP. Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N Y Acad Sci 2012; 1271:37-43.
33. Larsson SC, Wolk A. Obesity and the risk of gallbladder cancer: A metaanalysis. Br J Cancer 2007; 96:1457-1461.
34. Lai HC, Chang SN, Lin CC, et al. Does diabetes mellitus with or without gallstones increase the risk of gallbladder cancer? Results from a populationbased cohort study. J Gastroenterol 2013; 48:856-865.
35. Ren HB, Yu T, Liu C, Li YQ. Diabetes mellitus and increased risk of biliary tract cancer: systematic review and meta-analysis. Cancer Causes Control 2011; 22:837-847.
36. Trivedi V,Gumaste VV, LiuS,BaumJ.Gallbladder cancer: Adenoma-carcinoma or dysplasia-carcinoma sequence? Gastroenterol Hepatol (N Y) 2008;4:735-737.
37. Barreto SG, Dutt A, Chaudhary A. A genetic model for gallbladder carcinogenesis and its dissemination. Ann Oncol 2014; 25:1086-1097.
38. Wistuba II, Miquel JF, Gazdar AF, Albores-Saavedra J. Gallbladder adenomas have molecular abnormalities different from those present in gallbladder carcinomas. Hum Pathol 1999; 30:21-25.
39. Litchfield JE. New research on precancerous conditions. New York: Nova Biomedical Books; 2007.
40. Roa I, Araya JC, Villaseca M, et al. Preneoplastic lesions and gallbladder cancer: An estimate of the period required for progression. Gastroenterology 1996; 111:232-236.
41. Roa EI, Munoz NS, Ibacache SG, Aretxabala UX. Natural history of gallbladder cancer. Analysis of biopsy specimens. Rev Med Chil 2009; 137:873-880.
42. Roa I, de Aretxabala X, Araya JC, et al. Incipient gallbladder carcinoma. Clinical and pathological study and prognosis in 196 cases. Rev Med Chil 2001; 129:1113-1120.
43. Roa I, de Aretxabala X, Araya JC, Roa J. Preneoplastic lesions in gallbladder cancer. J Surg Oncol 2006; 93:615-623.
44. Albores-Saavedra J, Chablé-Montero F, Gonzŕlez-Romo MA, et al. Adenomas of the gallbladder. Morphologic features, expression of gastric and intestinal mucins, and incidence of high-grade dysplasia/carcinoma in situ and invasive carcinoma. Hum Pathol 2012; 43:1506-1513.
45. Roa I, de Aretxabala X, Morgan R, et al. Clinicopathological features of gallbladder polyps and adenomas. Rev Med Chil 2004; 132:673-679.
46. Kozuka S, Tsubone N, Yasui A, Hachisuka K. Relation of adenoma to carcinoma in the gallbladder. Cancer 1982; 50:2226-2234.
47. Shindoh J, de Aretxabala X, Aloia TA, et al.Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: An international multicenter study 10.1097/SLA.0000000000000728. Ann Surg 2014. [Epub ahead of print]
48. Roa I, Araya JC, Wistuba I, de Aretxabala X. Gallbladder cancer: Anatomic and anatomo-pathologic considerations. Rev Med Chil 1990; 118:572-579.
49. Adsay NV, Bagci P, Tajiri T, et al. Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers: pitfalls and practical limitations of the current AJCC/UICC TNM staging system and opportunities for improvement. Semin Diagn Pathol 2012; 29:127-141.
50. Goldin RD, Roa JC. Gallbladder cancer: A morphological and molecular update. Histopathology 2009; 55:218-229.
51. Grieser C, Denecke T, Schmidt SC. An unusual cause of recurrent acute abdominal pain. Gastroenterology 2012; 142:e5-e6.
52. Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer 2004; 4:695-706.
53. Wistuba II, Tang M, Maitra A, et al. Genome-wide allelotyping analysis reveals multiple sites of allelic loss in gallbladder carcinoma. Cancer Res 2001; 61:3795-3800.
54. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
55. Emory University. Project CGA. http://www.cancerquest.org/tumor-suppres sors-table.html. 2010. [Accessed 5 December 2014]
56. Vivanco I. Targeting molecular addictions in cancer. Br J Cancer 2014; 111:2033-2038.
57. Rashid A, Ueki T, Gao YT, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: A population-based study in China. Clin Cancer Res 2002; 8:3156-3163.
58. Jain K, Mohapatra T, Das P, et al. Sequential occurrence of preneoplastic lesions and accumulation of loss of heterozygosity in patients with gallbladder stones suggest causal association with gallbladder cancer 10.1097/SLA. 0000000000000495. Ann Surg 2014; 260:1073-1080.
59. Kagohara LT, Schussel JL, Subbannayya T, et al. Global and gene-specific DNA methylation pattern discriminates cholecystitis from gallbladder cancer patients in Chile 10.2217/fon 14. 165. Future Oncol 2015; 11:233-249.
60. Black JC, Whetstine JR. Chromatin landscape: methylation beyond transcription. Epigenetics 2011; 6:9-15.
61. Letelier P, Brebi P, Tapia O, Roa JC. DNA promoter methylation as a diagnostic and therapeutic biomarker in gallbladder cancer. Clin Epigenetics 2012; 4:11.
62. Deshpande V, Nduaguba A, Zimmerman SM, et al. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer 2011; 11:60.
63. Pignochino Y, Sarotto I, Peraldo-Neia C, et al. Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas. BMC Cancer 2010; 10:631.
64. Riener MO, Bawohl M, Clavien PA, Jochum W. Rare PIK3CA hotspot mutations in carcinomas of the biliary tract. Genes Chromosomes Cancer 2008; 47:363-367.
65. Rai R, Tewari M, Kumar M, et al. p53: its alteration and gallbladder cancer. Eur J Cancer Prev 2011; 20:77-85.
66. Roa JC, Anabalon L, Roa I, et al. Promoter methylation profile in gallbladder cancer. J Gastroenterol 2006; 41:269-275.
67. Ji X, Tang J, Halberg R, et al. Distinguishing between cancer driver and passenger gene alteration candidates via cross-species comparison: A pilot study. BMC Cancer 2010; 10:426.
68. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science 2013; 339:1546-1558.
69. Li M, Zhang Z, Li X, et al. Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway [10. 1038/ng. 3030]. Nat Genet 2014.
70. He ML, Chen Y, Chen Q, et al. Multiple gene dysfunctions lead to high cancersusceptibility: evidences from a whole-exome sequencing study. Am J Cancer Res 2011; 1:562-573.
71. Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet 2013; 45:1470-1473.
72. Javle M, Rashid A, Churi C, et al. Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol 2014; 45:701-708.
73. Kumari N, Corless CL, Warrick A, et al. Mutation profiling in gallbladder cancer in Indian population. Indian J Pathol Microbiol 2014; 57:9-12.
74. Roa I, de Toro G, Schalper K, et al. Overexpression of the HER2/neu gene: A new therapeutic possibility for patients with advanced gallbladder cancer. Gastrointest Cancer Res 2014; 7:42-48.
75. Pai RK, Mojtahed K. Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas. Appl Immunohistochem Mol Morphol 2011; 19:133-140.
76. Faris JE, Zhu AX. Targeted therapy for biliary tract cancers. J Hepatobiliary Pancreat Sci 2012; 19:326-336.
77. Subbiah IM, Subbiah V, Tsimberidou AM, et al. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget 2013; 4:153-162.
78. Leal P, Garcia P, Sandoval A, et al. AKT/mTOR substrate P70S6K is frequently phosphorylated in gallbladder cancer tissue and cell lines. Onco Targets Ther 2013; 6:1373-1384.
79. Zong H, Yin B, Zhou H, et al. Inhibition of mTOR pathway attenuates migration and invasion of gallbladder cancer via EMT inhibition. Mol Biol Rep 2014; 41:4507-4512.
80. Li Q, Yang Z. Expression of phospho-ERK1/2 and PI3-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. J Exp Clin Cancer Res 2009; 28:65.
81. Wu XS, Wang XA, Wu WG, et al. MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. Cancer Biol Ther 2014; 15:806-814.
82. Zhang P, Jiang G, Gao J, et al. SAHA down-regulates the expression of indoleamine 2,3-dioxygenase via inhibition of the JAK/STAT1 signaling pathway in gallbladder carcinoma cells. Oncol Rep 2013; 29:269-275.
83. Iwase R, Haruki K, Fujiwara Y, et al. Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-kB activation. J Surg Res 2013; 184:605-612.
84. Koninger J, di Mola FF, Di Sebastiano P, et al. Transforming growth factor-beta pathway is activated in cholecystolithiasis. Langenbecks Arch Surg 2005; 390:21-28.
85. Huang M, Shen A, Ding J, Geng M. Molecularly targeted cancer therapy: some lessons from the past decade. Trends Pharmacol Sci 2014; 35:41-50.
86. Roa I, de Aretxabala X, Lantadilla S, Munoz S. ERCC1 (excision repair crosscomplementing 1) expression in pT2 gallbladder cancer is a prognostic factor. Histol Histopathol 2011; 26:37-43.